Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
Conditions
Interventions
BCX7353 capsules
Placebo oral capsule
Locations
47
United States
Study center
Birmingham, Alabama, United States
Study center
Scottsdale, Arizona, United States
Study center
Little Rock, Arkansas, United States
Study Center
San Diego, California, United States
Study center
Santa Monica, California, United States
Study Center
Walnut Creek, California, United States
Start Date
February 6, 2018
Primary Completion Date
April 10, 2019
Completion Date
April 6, 2022
Last Updated
June 26, 2023
NCT06628531
NCT07298447
NCT06706206
NCT06960213
NCT06788275
NCT06842823
Lead Sponsor
BioCryst Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions